These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 18657474)

  • 1. Quantitative and qualitative changes in the resting electrocardiograph after percutaneous transluminal septal myocardial ablation for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.
    Thai WE; Antonis PR; Hope SA; Meredith IT
    Heart Lung Circ; 2008 Oct; 17(5):364-9. PubMed ID: 18657474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delayed electrocardiographic changes after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy.
    Guo H; Wang P; Xing Y; Peng F; Jiang J; Yang B; You B; Qiu Y; Lee JD
    J Electrocardiol; 2007 Oct; 40(4):356.e1-6. PubMed ID: 17316677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of complete heart block after transcoronary ablation of septal hypertrophy: results of a prospective electrophysiological investigation in 172 patients with hypertrophic obstructive cardiomyopathy.
    Lawrenz T; Lieder F; Bartelsmeier M; Leuner C; Borchert B; Meyer zu Vilsendorf D; Strunk-Mueller C; Reinhardt J; Feuchtl A; Stellbrink C; Kuhn H
    J Am Coll Cardiol; 2007 Jun; 49(24):2356-63. PubMed ID: 17572252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The effect on electrocardiographic and cardiac autonomic function after percutaneous transluminal septal myocardial ablation in patients with hypertrophic obstructive cardiomyopathy].
    Xing YB; Guo HY; Wang P; You BQ; Chen JZ
    Zhonghua Xin Xue Guan Bing Za Zhi; 2007 Aug; 35(8):731-4. PubMed ID: 17963633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complications of percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy.
    Zhang W; Li Z; Zhang M; Yuan L; Guan R; Hou A; Jin Y; Deng Z
    Chin Med J (Engl); 2002 Sep; 115(9):1283-6. PubMed ID: 12411095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conduction system abnormalities in patients with obstructive hypertrophic cardiomyopathy following septal reduction interventions.
    Qin JX; Shiota T; Lever HM; Asher CR; Popović ZB; Greenberg NL; Agler DA; Drinko JK; Smedira NG; Tuzcu EM; Lytle BW; Thomas JD
    Am J Cardiol; 2004 Jan; 93(2):171-5. PubMed ID: 14715342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Percutaneous versus surgical treatment for patients with hypertrophic obstructive cardiomyopathy and enlarged anterior mitral valve leaflets.
    van der Lee C; ten Cate FJ; Geleijnse ML; Kofflard MJ; Pedone C; van Herwerden LA; Biagini E; Vletter WB; Serruys PW
    Circulation; 2005 Jul; 112(4):482-8. PubMed ID: 16027255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progressive decrease of outflow gradient and septum thickness after percutaneous alcoholization of the interventricular septum in hypertrophic obstructive cardiomyopathy.
    Airoldi F; Di Mario C; Catanoso A; Dharmadhikari A; Tzifos V; Anzuini A; Carlino M; Briguori C; Montorfano M; Vaghetti M; Tolaro S; Colombo A
    Ital Heart J; 2000 Mar; 1(3):200-6. PubMed ID: 10806987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prognostic value of acute heart block after alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy].
    Hou AJ; Duan N; Yang L; Li HJ; Li ZQ; Yuan L; Guan RM; Liu Y
    Zhonghua Xin Xue Guan Bing Za Zhi; 2009 Feb; 37(2):149-51. PubMed ID: 19719994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety and efficacy of slow pathway ablation in patients with atrioventricular nodal re-entrant tachycardia and pre-existing prolonged PR interval.
    Pasquié JL; Scalzi J; Macia JC; Leclercq F; Grolleau-Raoux R
    Europace; 2006 Feb; 8(2):129-33. PubMed ID: 16627424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Non-pharmacologic therapy of hypertrophic obstructive cardiomyopathy--results of therapy based on percutaneous transluminal septal myocardial ablation compared with results of dual-chamber cardiac pacing].
    Krejcí J; Groch L; Meluzín J; Vykypel T; Halámek J; Vitovec J
    Vnitr Lek; 2006 Apr; 52(4):313-20. PubMed ID: 16755987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy.
    Sorajja P; Valeti U; Nishimura RA; Ommen SR; Rihal CS; Gersh BJ; Hodge DO; Schaff HV; Holmes DR
    Circulation; 2008 Jul; 118(2):131-9. PubMed ID: 18591440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcome of percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: a Scandinavian multicenter study.
    Jensen MK; Almaas VM; Jacobsson L; Hansen PR; Havndrup O; Aakhus S; Svane B; Hansen TF; Køber L; Endresen K; Eriksson MJ; Jørgensen E; Amlie JP; Gadler F; Bundgaard H
    Circ Cardiovasc Interv; 2011 Jun; 4(3):256-65. PubMed ID: 21540441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of clinical, echocardiographic, and procedural characteristics to predict outcome after percutaneous transluminal septal myocardial ablation.
    van der Lee C; Scholzel B; ten Berg JM; Geleijnse ML; Idzerda HH; van Domburg RT; Vletter WB; Serruys PW; ten Cate FJ
    Am J Cardiol; 2008 May; 101(9):1315-20. PubMed ID: 18435964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Predicting the risk of atrioventricular conduction lesions after percutaneous septal ablation for obstructive hypertrophic cardiomyopathy].
    Faber L; Seggewiss H; Welge D; Fassbender D; Ziemssen P; Schmidt HK; Gleichmann U; Horstkotte D
    Z Kardiol; 2003 Jan; 92(1):39-47. PubMed ID: 12545300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Occurrence of de novo sustained monomorphic ventricular tachycardia induced after percutaneous transluminal alcohol septal myocardial ablation for hypertrophic obstructive cardiomyopathy.
    Hori Y; Ueda M; Nakayama T; Saegusa N; Uehara M; Lee K; Sekine T; Daimon M; Kobayashi Y; Funabashi N; Komuro I
    Int J Cardiol; 2007 Jul; 119(3):403-7. PubMed ID: 17069908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of percutaneous transluminal septal myocardial ablation for obstructive hypertrophic cardiomyopathy on systolic and diastolic left ventricular function assessed by pressure-volume loops.
    Meliga E; Steendijk P; Valgimigli M; Ten Cate FJ; Serruys PW
    Am J Cardiol; 2008 Apr; 101(8):1179-84. PubMed ID: 18394455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Left ventricular electromechanical delay in patients with heart failure and normal QRS duration and in patients with right and left bundle branch block.
    Badano LP; Gaddi O; Peraldo C; Lupi G; Sitges M; Parthenakis F; Molteni S; Pagliuca MR; Sassone B; Di Stefano P; De Santo T; Menozzi C; Brignole M
    Europace; 2007 Jan; 9(1):41-7. PubMed ID: 17224421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Left ventricular conduction delays induced by right ventricular apical pacing: effect of left ventricular dysfunction and bundle branch block.
    Varma N
    J Cardiovasc Electrophysiol; 2008 Feb; 19(2):114-22. PubMed ID: 17971145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extent of myocardial infarction and reverse remodeling assessed by cardiac magnetic resonance in patients with and without right bundle branch block following alcohol septal ablation for obstructive hypertrophic cardiomyopathy.
    McCann GP; Van Dockum WG; Beek AM; Nijveldt R; Ten Cate FJ; Ten Berg JM; Van Rossum AC
    Am J Cardiol; 2007 Feb; 99(4):563-7. PubMed ID: 17293204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.